中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | (-)-cis-khellactone | 54712-23-1 | C14H14O5 | 262.262 |
—— | hystrixarin | 80058-06-6 | C19H22O6 | 346.38 |
—— | junosmarin | 85165-97-5 | C19H22O6 | 346.38 |
—— | (+)-3'-decanoyl-cis-khellactone | 870481-50-8 | C24H32O6 | 416.514 |
—— | campestrinol | 84458-88-8 | C24H26O7 | 426.466 |
—— | cis-khellactone 3'-O-β-D-glucopyranoside | 86940-46-7 | C20H24O10 | 424.405 |
狭缝芹素 | suksdorfin | 53023-17-9 | C21H24O7 | 388.417 |
(+)-沙米丁 | (+)-samidin | 477-33-8 | C21H22O7 | 386.401 |
北美芹素 | pteryxin | 13161-75-6 | C21H22O7 | 386.401 |
—— | 3'(R)-acetoxy-4'(S)-angeloyloxy-3',4'-dihydroseselin | —— | C21H22O7 | 386.401 |
—— | hyuganin A | —— | C24H28O7 | 428.482 |
—— | hyuganin E | 809271-86-1 | C21H24O9 | 420.416 |
—— | isoepoxypteryxin | 11350-35-9 | C21H22O8 | 402.401 |
邪蒿素 | seseline | 523-59-1 | C14H12O3 | 228.247 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
(9R,10S)-9,10-二氢-9-羟基-10-甲氧基-8,8-二甲基-2H,8H-苯并[1,2-B:3,4-B']二吡喃-2-酮 | (9R,10S)-9-hydroxy-10-methoxy-8,8-dimethyl-9,10-dihydro-2H,8H-pyrano[2,3-f]chromen-2-one | 23733-92-8 | C15H16O5 | 276.289 |
(9R,10R)-9,10-二氢-9-羟基-10-甲氧基-8,8-二甲基-2H,8H-苯并[1,2-B:3,4-B']二吡喃-2-酮 | cis-4'-O-methylkhellactone | 20107-13-5 | C15H16O5 | 276.289 |
—— | (-)-trans-ethylkhellactone | 4969-82-8 | C16H18O5 | 290.316 |
—— | 3′,4′-di-O-acetyl-cis-khellactone | 312728-69-1 | C18H18O7 | 346.337 |
—— | 3'-keto,3',4'-dihydroseselin | 2221-67-2 | C14H12O4 | 244.247 |
P-glycoprotein (Pgp) overexpression in tumour cells leads to multidrug resistance (MDR) and causes failure in cancer chemotherapy. We have previously identified (±)-praeruptorin A (PA) as a potential lead compound for Pgp modulators. In this study we investigated the MDR-reversing activities of PA derivatives.
Series 7,8-pyranocoumarins with various C-3′ and C-4′ side chains had been semi-synthesized and their MDR-reversing activity was investigated in Pgp-overexpressing MDR tumour cell line HepG2/Dox and in a KB V1 xenograft animal model.
All 7,8-pyranocoumarins exhibited equal or higher activity in modulating Pgp. DCK (12), DMDCK (15), 16, 21, 23 and 24 at 4 µm achieved 91%∼99% decrease in IC50 value (concentration inhibiting cell growth by 50%) of anticancer agents vinblastine, doxorubicin, puromycin and paclitaxel, and were more active than others. DMDCK also remarkably enhanced the growth inhibitory effect of paclitaxel on KB V1 xenografts (P < 0.05), showing a potency required for clinical usage. Mechanistic studies suggested that these 7,8-pyranocoumarins might reverse Pgp-MDR through directly binding to substrate binding site(s) or allosteric site(s) on Pgp therefore impairing Pgp-mediated drug transport.
Results from the study suggested that 3′-O, 4′-O-aromatic acyl substituted 7,8-pyranocoumarins could serve as a new class of Pgp modulator. Acyls play an important role in maintaining and enhancing the Pgp-modulating ability of pyranocoumarins. 3,4-Dimethoxyl substituted aromatic acyls, bearing a methoxy that might interact with Pgp as hydrogen bond accepter, were shown to be the most potent for reversing MDR.